Why the study?
Does rivaroxaban prevent thromboembolism and major bleeding compared to warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation?
Does rivaroxaban prevent thromboembolism and major bleeding compared to warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation?
In Japanese patients undergoing catheter ablation for atrial fibrillation, perioperative use of rivaroxaban was associated with similarly low rates of thromboembolism and major bleeding compared to warfarin.
Answers are grounded in this paper and cite their sources.
Rivaroxaban was associated with similarly low event rates to warfarin; leaves open whether randomized trials would confirm equivalence in Japanese AF ablation.
BACKGROUND: Catheter ablation (CA) is a common treatment for atrial fibrillation (AF). Although rivaroxaban is increasingly used as a substitute for warfarin, its safety and efficacy during CA have not been established in Japanese patients. In the present study we explored the efficacy/safety of rivaroxaban during the CA perioperative period. METHODS AND RESULTS: We prospectively enrolled Japanese AF patients scheduled for CA who had received either rivaroxaban (rivaroxaban cohort, JACRE-R) or warfarin (warfarin cohort, JACRE-W) during the perioperative period. Primary outcome was a composite of thromboembolism and major bleeding within 30 days after CA. In JACRE-R and JACRE-W, 1,118 (median age, 65 years) and 204 patients (median, 69 years) were enrolled from 42 and 22 institutions, respectively. In JACRE-R, the primary outcome occurred in 7 patients (0.6%), comprising thromboembolism in 2 and major bleeding in 5. Non-major bleeding occurred in 27 patients (2.4%), and the incidence was significantly lower in patients without heparin bridging (n=572) than in those with heparin bridging (n=546). In JACRE-W, the primary outcome occurred in 3 patients (1.5%), all of which were major bleeding. After adjustment for patients' characteristics, no significant difference was observed between the JACRE-R and JACRE-W cohorts for the primary outcome. CONCLUSIONS: The rates of thromboembolism and major bleeding events during the AF ablation perioperative period in Japanese patients treated with rivaroxaban was as low as in those treated with warfarin. (Circ J 2016; 80: 2295-2301).
No takes yet. Share an insight, caveat, or question.
Okumura et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: